Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue Digestive Diseases and Sciences Année : 2016

Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases

Résumé

Local or national policy, patients' preferences, safety and/or economic concerns, or reimbursement issues may dictate stopping drug in inflammatory bowel diseases (IBD) patients. Sustained deep remission is an important predictor of a better outcome after anti-tumor necrosis (TNF) factor therapy discontinuation, including infliximab (IFX) in IBD patients, but this is not sufficient to prevent future relapse in these patients. In IBD patients under combotherapy, trough level of infliximab (TRI) could be helpful to choose stopping one of the two drugs. In patients on IFX monotherapy, TRI could help to decide reduction of drug dosing, particularly in IBD patients with supratherapeutic trough levels. Incidental findings of undetectable TRI in patients with deep remission may identify a subset of patients who may be considered for IFX cessation. Controlled trials further assessing this issue are eagerly awaited. Pending these trials, clear international recommendations for discontinuing anti-TNF therapy are needed.
Fichier non déposé

Dates et versions

hal-01682890 , version 1 (12-01-2018)

Identifiants

Citer

Nicolas Williet, Stéphane Paul, Laurent Peyrin-Biroulet, Xavier Roblin. Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2016, 61 (4), pp.990-995. ⟨10.1007/s10620-015-3984-2⟩. ⟨hal-01682890⟩
27 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More